Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,178.67
+3.34 (+0.28%)
Streaming Delayed Price
Updated: 3:53 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture?
March 01, 2024
Via
Benzinga
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts
February 27, 2024
Via
Benzinga
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
February 26, 2024
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.
Via
Benzinga
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
February 26, 2024
Via
Benzinga
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
February 23, 2024
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
Via
Investor's Business Daily
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
February 22, 2024
Via
Benzinga
2 No-Brainer Biotech Stocks to Buy Right Now
February 21, 2024
These stocks are used to beating the market.
Via
The Motley Fool
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 2/20 Morning Trading
February 20, 2024
Via
Investor Brand Network
$100 Invested In This Stock 20 Years Ago Would Be Worth $6,400 Today
February 06, 2024
Via
Benzinga
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
February 23, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
February 21, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
February 20, 2024
The FDA put studies in eczema and asthma treatment on clinical hold.
Via
Investor's Business Daily
Exposures
Product Safety
Starbucks, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
February 20, 2024
The Nasdaq 100 closed lower by over 150 points on Friday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
2 Top Growth Stocks to Buy With $1,000 Right Now
February 18, 2024
Even a modest starting investment in the right stocks could pay off in the years ahead.
Via
The Motley Fool
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
February 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
February 12, 2024
Via
Benzinga
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
February 09, 2024
There's room for multiple winners in the fast-growing weight-loss market.
Via
The Motley Fool
The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition
February 06, 2024
Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Regeneron Announces Investor Conference Presentations
February 06, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast
February 06, 2024
4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70.
Via
Benzinga
Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
February 06, 2024
Via
Benzinga
Stock-Split Watch: Could These 2 Market-Beaters Be Next?
February 06, 2024
Investors might continue bidding up shares of these companies regardless.
Via
The Motley Fool
Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today?
February 05, 2024
4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity.
Via
Benzinga
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?
February 02, 2024
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.
Via
Benzinga
The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High
February 02, 2024
Shares usually rally on Eylea news, but Regeneron stock is on the rise following fourth-quarter beats from two other products.
Via
Investor's Business Daily
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year
February 02, 2024
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc.
Via
Benzinga
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
February 02, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.